193 related articles for article (PubMed ID: 37537630)
1. Decoding the prognostic significance of integrator complex subunit 9 (INTS9) in glioma: links to TP53 mutations, E2F signaling, and inflammatory microenvironments.
Lin YC; Chang PC; Hueng DY; Huang SM; Li YF
Cancer Cell Int; 2023 Aug; 23(1):154. PubMed ID: 37537630
[TBL] [Abstract][Full Text] [Related]
2. Ancient ubiquitous protein 1 (AUP1) is a prognostic biomarker connected with TP53 mutation and the inflamed microenvironments in glioma.
Chang PC; Lin YC; Yen HJ; Hueng DY; Huang SM; Li YF
Cancer Cell Int; 2023 Apr; 23(1):62. PubMed ID: 37029364
[TBL] [Abstract][Full Text] [Related]
3.
Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
Front Immunol; 2022; 13():974346. PubMed ID: 36275718
[TBL] [Abstract][Full Text] [Related]
4. Tumor mutational burden is associated with poor outcomes in diffuse glioma.
Wang L; Ge J; Lan Y; Shi Y; Luo Y; Tan Y; Liang M; Deng S; Zhang X; Wang W; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Mar; 20(1):213. PubMed ID: 32164609
[TBL] [Abstract][Full Text] [Related]
5. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
[TBL] [Abstract][Full Text] [Related]
6. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
7. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
8. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
9. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
10. Connective tissue growth factor as an unfavorable prognostic marker promotes the proliferation, migration, and invasion of gliomas.
Song ZB; Yang HP; Xu AQ; Zhan ZM; Song Y; Li ZY
Chin Med J (Engl); 2020 Mar; 133(6):670-678. PubMed ID: 32197031
[TBL] [Abstract][Full Text] [Related]
11. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
12. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma.
Chai RC; Wang N; Chang YZ; Zhang KN; Li JJ; Niu JJ; Wu F; Liu YQ; Wang YZ
Cancer Cell Int; 2019; 19():155. PubMed ID: 31171919
[TBL] [Abstract][Full Text] [Related]
13. CKAP2L Knockdown Exerts Antitumor Effects by Increasing miR-4496 in Glioblastoma Cell Lines.
Li YF; Tsai WC; Chou CH; Huang LC; Huang SM; Hueng DY; Tsai CK
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375517
[TBL] [Abstract][Full Text] [Related]
14. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
[TBL] [Abstract][Full Text] [Related]
15. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
16.
Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of a risk signature based on extracellular matrix-related genes in gliomas.
Liu J; Li G
Medicine (Baltimore); 2021 Apr; 100(16):e25603. PubMed ID: 33879726
[TBL] [Abstract][Full Text] [Related]
18. Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma.
Chen L; Xiong Z; Zhao H; Teng C; Liu H; Huang Q; Wanggou S; Li X
Front Oncol; 2022; 12():889351. PubMed ID: 36033495
[TBL] [Abstract][Full Text] [Related]
19. Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma.
Zou R; Zhong X; Liang K; Zhi C; Chen D; Xu Z; Zhang J; Liao D; Lai M; Weng Y; Peng H; Pang X; Ji Y; Ke Y; Zhang H; Wang Z; Wang Y
BMC Cancer; 2023 May; 23(1):403. PubMed ID: 37142967
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of transferrin receptor protein 1 for predicting prognosis and immune infiltration in lower grade glioma.
Wu H; He H; Huang J; Wang C; Dong Y; Lin R; Cheng Z; Qiu Q; Hong L
Front Mol Neurosci; 2022; 15():972308. PubMed ID: 36483569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
